Previous Close | 0.0350 |
Open | 0.0400 |
Bid | 0.0350 x 0 |
Ask | 0.0500 x 0 |
Day's Range | 0.0400 - 0.0500 |
52 Week Range | 0.0200 - 0.1100 |
Volume | |
Avg. Volume | 200,182 |
Market Cap | 6.632M |
Beta (5Y Monthly) | 0.61 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0110 |
Earnings Date | Nov 01, 2022 - Nov 07, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 2.52 |
VANCOUVER, British Columbia, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), is pleased to announce that Health Canada has approved Zimed® PF (Bimatoprost 0.03%) for the reduction of elevated intraocular pressure (IOP) in patients with open-angled glaucoma or ocular hypertension. Affecting more than 700,000 people in Canada, glaucoma is one of the leading causes of blindness in North America. Zimed® PF is the first prostagland
Aequus Pharmaceuticals ( CVE:AQS ) Third Quarter 2022 Results Key Financial Results Revenue: CA$347.9k (down 51% from...
VANCOUVER, British Columbia, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“Aequus” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing, and promoting differentiated products, today reported financial results for the quarter ended September 30, 2022 (“Third Quarter 2022”) and associated Company developments. Unless otherwise noted, all figures are in Canadian currency. Financial Report Highlights Aequus reported